Ac-VLPE-FMK  (Synonyms: Ac-Val-Leu-Pro-Glu(OMe)-CH2F)

Ac-VLPE-FMK, a tetrapeptidyl mono-fluoromethyl ketone (m-FMK), is a Cat-B and Cat-L inhibitor. Ac-VLPE-FMK can be used for the research of cancer aggressiveness^[1][2].

Ac-VLPE-FMK (2 μM) significantly affects the cleavage of probe Ac-PLVQ-AMC by human recombinant CtsB and L^[1].
Ac-VLPE-FMK (30 min) inhibits the generation of the fluorescence derived from the cleavage of the substrate Ac-PLVQ-AMC in 769-p and A498 cells^[1].
Ac-VLPE-FMK (2.5-250 μM; 24-72 h) does not affect renal cancer cell viability, but influences cell migration rate, cellular adhesion, colony formation, and markers expression in renal cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

528.61

C₂₅H₄₁FN₄O₇

2679825-27-3

Solid

White to off-white

O=C(N(CCC1)[C@@H]1C(N[C@H](C(CF)=O)CCC(OC)=O)=O)[C@H](CC(C)C)NC([C@H](C(C)C)NC(C)=O)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Rudzińska M, et, al. Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype. Cancers (Basel). 2020 May 21;12(5):1310.  [Content Brief]

  [2]. Citarella A, et, al. Peptidyl Fluoromethyl Ketones and Their Applications in Medicinal Chemistry. Molecules. 2020 Sep 3;25(17):4031.  [Content Brief]